# NCT03740529 (NCT03740529)

> A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03740529
- Phase: PHASE1, PHASE2
- Status: COMPLETED
- Sponsor: Loxo Oncology, Inc.
- Conditions: Chronic Lymphocytic Leukemia; Waldenstrom Macroglobulinemia; Mantle Cell Lymphoma; Marginal Zone Lymphoma; B-cell Lymphoma; Small Lymphocytic Lymphoma
- Interventions: Pirtobrutinib; Venetoclax; Rituximab
- Enrollment: 803
- Primary outcome: Maximum Tolerated Dose (MTD)
- Primary outcome: Recommended dose for further study
- Primary outcome: To assess the preliminary anti-tumor activity of pirtobrutinib based on ORR as assessed by an Independent Review Committee (IRC).
- Primary outcome: To evaluate the safety of pirtobrutinib in combination with venetoclax (Arm A) by assessing incidence and severity of treatment-emergent adverse events as determined by CTCAE v5.0
- Primary outcome: To evaluate the safety of pirtobrutinib in combination with venetoclax and rituximab (Arm B) by assessing incidence and severity of treatment-emergent adverse events as determined by CTCAE v5.0

## Commentary we found

- YouTube: 108
- Podcasts: 95
- X threads: 48
- X videos: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct03740529

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03740529", "email": "<work email>"}; the inbox owner confirms by the emailed link.